Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Carl Regillo, Hawaiian Eye and Retina 2021: Geographic Atrophy – Current Therapeutic Approaches and Future Prospects

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 3rd 2021

It was a pleasure to catch up with Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA), who talked us through the therapeutic approaches currently in clinical trial investigation for the treatment of geographic atrophy, and his views on exciting future prospects for treatment.

Questions

  1. Could you give us a brief overview of the therapeutic approaches currently in clinical trial investigation for the treatment of geographic atrophy (GA)? (00:17)
  2. Of these, which has shown the most promise to date? (01:04)
  3. What do you consider the most exciting future prospects for the treatment of GA? (02:08)

Speaker Disclosure: Carl Regillo has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of Hawaiian Eye and Retina 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup